While most physicians rely on serum creatinine levels to determine kidney function, it’s not the most reliable indicator, according to a nephrologist who presented at the International Society for Computed Tomography on May 18. Instead, he suggested providers look at the estimated glomerular filtration rate (eGFR). In acutely ill patients in particular look at the changing serum creatinine (sCR) levels and not the specific values or specific eGFRs, he said.
While most physicians rely on serum creatinine levels to determine kidney function, it’s not the most reliable indicator, according to a nephrologist who presented at the International Society for Computed Tomography on May 18. Instead, he suggested providers look at the estimated glomerular filtration rate (eGFR). In acutely ill patients in particular look at the changing serum creatinine (sCR) levels and not the specific values or specific eGFRs, he said.
It’s important to screen patients prior to getting a contrast-enhanced CT to determine whether they are at risk for acute kidney injury, previously known as acute kidney failure. Acute kidney injury is defined as an abrupt loss of kidney function, usually over days, marked by changing sCR. Contrast administration can exacerbate acute kidney injury.
Dr. Steven D. Weisbord, an assistant professor of medicine in the renal section at VA Pittsburgh Healthcare System, suggests screening patients’ sCR if they have one or more of the following:
A better indication of kidney function, however, is eGFR. For instance, two patients can have the same sCr of 1.5, leading to a misinterpretation, while their eGFRs are 59 mL/min and 36 mL/min.
“Even patients with serum creatinine of 1.2 can have abnormal eGFR,” he said. “Patients can have normal serum creatinine levels and eGFRs that are very abnormal.”
Weisbord cited a study that appeared five years ago and illustrates a pronounced difference in women between sCr and eGFR. The women had sCrs of 0.9 or 1 and eGFRs that put them at the stage III chronic kidney disease, which is an eGFR of 30 to 60 (J Am Soc Nephrol 2005;16:2439-2448). In another example, women with sCr of 1.6 had eGFRs of less than 30, which is stage IV chronic kidney disease.
“Serum creatinine is not a good assessment of what the patient’s renal function is,” he said.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.